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Summary
The signals and molecular mechanisms that regulate the replication of terminally differentiated b cells are unknown. Here,
we report the identification and characterization of transmembrane protein 27 (Tmem27, collectrin) in pancreatic b cells.
Expression of Tmem27 is reduced in Tcf1–/– mice and is increased in islets of mouse models with hypertrophy of the endo-
crine pancreas. Tmem27 forms dimers and its extracellular domain is glycosylated, cleaved and shed from the plasmamem-
brane of b cells. This cleavage process is b cell specific and does not occur in other cell types. Overexpression of full-length
Tmem27, but not the truncated or soluble protein, leads to increased thymidine incorporation, whereas silencing of Tmem27
using RNAi results in a reduction of cell replication. Furthermore, transgenic mice with increased expression of Tmem27 in
pancreatic b cells exhibit increased b cellmass. Our results identify a pancreatic b cell transmembrane protein that regulates
cell growth of pancreatic islets.Introduction
Beta cell hyperplasia is an important adaptive mechanism
to maintain normoglycemia during physiological growth and in
obesity. Increasing evidence suggests that b cell mass is dy-
namic and that increased demands on insulin secretion in insulin
resistance and pregnancy can lead to rapid and marked
changes in b cell mass (Bruning et al., 1997; Accili, 2001; Bonner-
Weir, 2000a; Sorenson and Brelje, 1997). The mass of b cells is
governed by the balance of b cell growth (replication) and by
b cell death (apoptosis) (Lingohr et al., 2002; Butler et al., 2003;
Flier et al., 2001; Bonner-Weir, 2000b). However, the identity
of the factors that control b cell mass remain elusive. Under-
standing how b cell mass is regulated is important to design
rational approaches to prevent pancreatic b cell loss in insulin-
resistant states and to expand b cells for transplantation in
type 1 diabetes.
During development, b cells are generated from a population
of pancreatic progenitor cells (Edlund, 2002; Wilson et al., 2003).
The b cells that differentiate from progenitor cells are postmi-
totic, and direct lineage tracing studies indicate that a population
of progenitor cells persists throughout embryogenesis to allow
the differentiation of new b cells (Gu et al., 2002; Gradwohl
et al., 2000; Dor et al., 2004). In the neonatal period new b cells
are formed by replication of differentiated b cells, which results
in a massive increase in b cell mass (Finegood et al., 1995;
Svenstrup et al., 2002). In adulthood there is little increase in
the b cell number except in conditions of increased demand.
During pregnancy a marked hyperplasia of b cells is observed
both in rodents and man. This is due to increased mitotic activity
of b cells exposed to placental lactogen (PL), prolactin (PRL),
and growth hormone (GH) (Svenstrup et al., 2002; Parsons
et al., 1995; Scaglia et al., 1995). The growth stimulatory signals
in pathological insulin resistant states are less well understood.
Several mouse models of insulin resistance and diabetes,
such as the ob/ob and db/db mice or mutant mice created byCELL METABOLISM : DECEMBER 2005 $ VOL. 2 $ COPYRIGHT ª 2005inactivation of the gene for insulin receptor substrate-1 (Irs-1)
or double heterozygous (DH) knockout of the insulin receptor
and Irs-1, exhibit marked islet hyperplasia (Bock et al., 2003; To-
mita et al., 1992; Kulkarni et al. 2002, 2004; Kahn, 2003). In con-
trast, loss of Irs-2 function leads to a dramatic reduction of b cells
and diabetes (Withers et al., 1998). Glucose itself is known to
stimulate b cell replication (Topp et al., 2004), however, many
of the above mouse models increase their total islet mass before
the onset of detectable hyperglycemia. Furthermore, in most
cases the hyperplastic response bears no relationship to the
level of hyperglycemia, suggesting that factors independent of
glucose are likely to contribute to the islet growth.
Endocrine pancreatic growth during development depends
on multiple transcription factors that display highly specific tem-
poral and spatial expression patterns that control mechanisms
for cell differentiation (Edlund, 2002). During early pancreatic de-
velopment, cell fate decisions and differentiation of endocrine
progenitor cells into hormone-producing islet cells are tightly
regulated by the sequential expression of specific transcription
factors (Wilson et al., 2003). The expression of these factors is
also important for maintaining normal pancreatic b cell function
in adult life. For instance, mutations in several transcription fac-
tors lead to a subtype of type 2 diabetes called maturity-onset
diabetes of the young (MODY), which are characterized by auto-
somal dominant inheritance, an early age of disease onset, and
development of marked hyperglycemia with a progressive im-
pairment in insulin secretion (Shih and Stoffel, 2002). The most
frequent form of MODY is caused by mutations in the gene en-
coding hepatocyte nuclear factor-1a (HNF-1a, TCF1). Mutant
mice with loss of Tcf1 function as well as transgenic mice ex-
pressing a naturally occurring dominant-negative form of human
TCF1(P291fsinsC) in pancreatic b cells develop progressive hy-
perglycemia due to impaired glucose-stimulated insulin secre-
tion (Hagenfeldt-Johansson et al., 2001; Yamagata et al., 2002).
Importantly, these mice exhibit a progressive reduction in
b cell number, proliferation rate, and pancreatic insulin content.ELSEVIER INC. DOI 10.1016/j.cmet.2005.11.001 385
A R T I C L EThese data indicate that Tcf-1 target genes are also required for
maintenance of normal b cell mass.
In this study we sought to identify target genes of Tcf-1 that
may be responsible of mediating b cell growth by comparing
gene expression profiles of Tcf-1–/– and wild-type littermates
in isolated pancreatic islets. This analysis led to the identification
of a transcript encoding transmembrane protein-27 (Tmem27)
that is markedly reduced in pancreatic islets of Tcf-1–/–, mice
compared to controls. Tmem27 was originally described as
a kidney-specific gene that is upregulated in an injury-induced
renal hypertrophy model and termed collectrin (Zhang et al.,
2001). In this study, we carried out a comprehensive biochemi-
cal and functional analysis that demonstrates that Tmem27 is
a stimulator of b cell replication in vitro and in vivo.
Results
Tmem27 expression is regulated by Tcf1
In an attempt to identify mitogenic factors in pancreatic b cells,
we compared gene expression in isolated pancreatic islets of
Tcf1–/– and wild-type littermates using Affymetrix oligonucleo-
tide expression arrays (see Supplemental Experimental Proce-
dures in the Supplemental Data available with this article online).
Two replicates were independently analyzed (deposited at
GEO-NCBI under accession number GSE3544). This analysis
identified a gene encoding a transmembrane-spanning protein
(Tmem27) that showed a 16-fold decrease in expression levels
of Tcf1–/– mice compared to controls. This result was confirmed
by RT-PCR in an independent group of animals (Figure 1A). To
study whether Tcf1 is a direct activator of Tmem27 transcription,
we analyzed the Tmem27 promoter and identified two putative
Tcf1 binding sites in its regulatory region that were conserved
between human and mouse (Figure 1B). We cloned an 815 bp
promoter region upstream of a luciferase reporter gene and
coexpressed it with a Tcf1 expression vector. Transient cotrans-
fection of Tcf1 and Tmem27 promoter led to a >5-fold activation
of luciferase activity (Figure 1C). When each Tcf1 site in the
Tmem27 promoter was selectively mutated, transcriptional ac-
tivation was reduced 70%–80% (Figure 1C). To demonstrate
binding of Tcf1 to these sites in vitro we carried out electropho-
retic gel mobility shift assays (EMSA) using double stranded
32P-labeled oligonucleotides containing the respective Tcf bind-
ing sites and MIN6 cell extracts. Figure 1D shows that the probe
shifted upon addition of nuclear extracts and that the binding
could be competed by adding increasing amounts of a known
binding site of the farnesoid X receptor promoter (Fxr) (Shih
et al., 2001). The specificity of protein binding to these sites
was also determined by further shifting the DNA-Tcf1 complex
using a specific anti-Tcf1 antiserum (Figure 1D). We also inves-
tigated if Tcf1 directly increases the expression of Tmem27 by
performing chromatin immunoprecipitation assays (ChIP). Tcf1
bound to the binding sites in the Tmem27 promoter of MIN6
cells and pancreatic islets but not in primary hepatocytes where
Tmem27 is not expressed (Figure 1E). These data confirm the
functionality of the Tcf1 binding sites in vivo and demonstrate
that Tcf1 is required for expression of Tmem27 in pancreatic
b cells.
TMEM27 is regulated during pancreas development
Expression of Tmem27 was studied during mouse pancreatic
development by immunohistochemical staining. In newborn386and adult pancreas, Tmem27 expression is restricted to b cells
of the islet (Figure 2, data not shown). During development of the
pancreas, Tmem27 is expressed at the earliest time when hor-
mone positive (mainly glucagon-positive cells) are apparent. At
embryonic days E10.5 and E12.5 Tmem27 expression is local-
ized in cells that express glucagon and insulin. During the
peak period of endocrine cell expansion, from embryonic day
13.5 to 18.5, Tmem27 mainly colocalizes with glucagon until
right before birth at E18.5 when it is also detected in insulin pos-
itive cells (Figure 2).
Tmem27 is an N-linked glycoprotein and forms
dimers in vivo
Tmem27 contains two predicted N-glycosylation sites at amino
acid residues 76 and 93, respectively. MIN6 cells were treated
with tunicamycin, an inhibitor of N-glycosylation (Waechter
and Lennarz, 1976). Cells were incubated in the presence of in-
creasing concentrations of tunicamycin and protein extracts
were prepared and analyzed by SDS-PAGE and immunoblot-
ting. Two bands with increased electrophoretic mobility ap-
peared upon treatment with tunicamycin, whereas the high mo-
lecular weight protein disappeared (Figure 3A). This result was
confirmed with an in vitro assay using N-glycanase, an enzyme
that releases intact N-linked glycans (data not shown). These
data suggest that Tmem27 is an N-linked glycoprotein.
We also carried out chemical cross-linking experiments to
test if Tmem27 protein exists as a multimer. MIN6 cell extracts
were incubated in the presence of two different cross-linking re-
agents: BMH (bismaleimidohexane), a membrane-permeable,
noncleavable compound and DTBP (dimethyl 3, 30-dithiobispro-
pionimidate), a membrane permeable, cleavable compound.
Following these treatments, an SDS-PAGE analysis was per-
formed under reducing and nonreducing conditions (Partis
et al., 1983; Geisler et al. 1992). Nonreducing western blots re-
vealed a band of exactly twice the molecular weight than under
reducing conditions. Cell extracts treated with BMH showed the
dimer protein in both reducing and nonreducing blots. In con-
trast, the protein dimers disappeared under reducing conditions
in the presence of DTBP (Figure 3B). The results were similar in
MIN6 cells that endogenously express Tmem27 and in N2A cells
that were transiently transfected with Tmem27 expression vec-
tor (data not shown).
Tmem27 is cleaved and shed from pancreatic b cells
Tmem27 has previously been predicted to be a transmembrane
protein with an N-terminal extracellular domain (Zhang et al.,
2001). We generated two antibodies (a-Tmem27N and
a-Tmem27C) that recognize peptides from extra- and intracellu-
lar domains of the protein, respectively (Figure 4A). In Western
blotting experiments anti-Tmem27C detected two bands in
whole-cell lysates of MIN6 cells (Figure 4B). The higher molecu-
lar weight band corresponded to the predicted molecular weight
of the glycosylated full-length protein. The lower band
(w25 kDa) was also specific since it could be detected by West-
ern blotting in cell lysates following transfection with a vector
(p-Tmem27.V5) expressing a C-terminal V5-Tag fusion protein
and an anti-V5 antibody (Figure 4B). We hypothesized that
Tmem27 might be cleaved and possibly shed, with the lower
molecular weight band representing the C-terminal transmem-
brane spanning part of Tmem27. We therefore analyzed super-
natants from different cell lines (including neuronal N2A cells,CELL METABOLISM : DECEMBER 2005
Regulation of pancreatic islet massFigure 1. Tmem27 expression is regulated by Tcf1
A) Tmem27 expression is decreased in the islets of Tcf1–/– mice compared to wild-type littermate controls. Expression levels were measured with RT-PCR, GAPDH was
used as a control. C, no DNA added; 2RT, no reverse transcriptase added to reaction.
B) Promoter analysis predicted two conserved Tcf binding sites in the upstream regulatory regions of human and mouse (bottom) Tmem27 genes, at260 and2117 base
pairs relative to the transcriptional start site. Human (top) and mouse (bottom) promoter sequences are aligned and Tcf binding sites are boxed in blue. A second site (red
box) denotes a putative Pdx-1 binding site. Highlighted sequences (green) indicate positions of the mutated Tcf binding sites.
C) Transcriptional activation assays in HepG2 cells that were transfected with pcDNA3 or pTcf1, pCMV-b-glactosidase, and the luciferase reporter gene using a 815 bp
Tmem27 mouse promoter (left panel). Tcf binding sites were mutated individually in the promoter sequence of the reporter vector and MIN6 cells were transfected with
vectors pT27luc-wt, pT27luc-m1 or p27luc-m2. Luciferase activity was normalized to b-galactosidase activity (right panel). Each value represents the mean of eight inde-
pendent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
D) EMSA analysis using oligonucleotides for Tcf binding sites 1 and 2 and whole-cell extracts of MIN6 cells. Competitor represents unlabeled double-stranded oligonu-
cleotides at increasing concentrations containing Tcf1 binding site of Fxr-1 promoter (Shih et al., 2001). The signal of the free probe at the bottom of the gel was cut off.
E) Chromatin immunoprecipitation assays in pancreatic islets and MIN6 cells demonstrate an in vivo interaction of Tcf1 with the promoter of Tmem27. A 150 bp region
spanning binding sites 1 and 2 was amplified with PCR. This interaction could not be found in primary hepatocytes, which do not express Tmem27. ChIP for Tcf1 was
validated in primary hepatocytes by amplification of a region in apolipoprotein M (apoM) promoter that spans the Tcf1 binding site (Richter et al., 2003).CELL METABOLISM : DECEMBER 2005 387
A R T I C L EFigure 2. Tmem27 is expressed in the developing mouse pancreas
Immunofluorescence of paraffin embedded pancreatic tissue from denoted time points in the mouse development with anti-Tmem27C, anti-Insulin and anti-Glucagon
antibodies. Developmental stages are indicated as embryonic (E) days.HepG2 cells, HEK293, and M-1 cells that were derived from
collecting ducts of the kidney and which exhibit endogenous ex-
pression of Tmem27). Cells were cultured for 48 hr in reduced-
serum medium and Tmem27 immunoreactivity in the superna-
tant was assayed by Western blotting using anti-Tmem27N.
We detected a band corresponding to a w25 kDa protein in
clonal b cell lines MIN6 and INS1E (Figure 4C, data not shown).
Interestingly, this protein can only be detected in the superna-
tant but not in whole-cell lysates, indicating that cleavage
occurs at the outer plasma membrane. This cleaved form of
Tmem27 could also be detected in media incubated with iso-
lated mouse pancreatic islets (Figure 4D). Treatment of super-
natants with N-Glycanase led to the disappearance of the
w25 kDa protein and the emergence of a band at w12 kDa,
the expected molecular weight of the unglycosylated N-terminal
domain of Tmem27 (Figure 4E). Interestingly, in spite of robust
expression of full-length protein in cell-lysates, we failed to de-
tect this band in Western blot analysis in the culture medium
of non-b cell lines that were transiently transfected with
a Tmem27 expression vector (pTmem27). In contrast, overex-
pression of Tmem27 in MIN6 and INS1E cells led to increased388amounts of soluble protein in their culture media (Figure 4C,
data not shown). We also showed that siRNA-mediated reduc-
tion in Tmem27 protein levels correlated with decreased levels
of the soluble form of Tmem27 in MIN6 cell supernatants (Fig-
ure 4F). Lastly, in order to irrefutably prove that N-terminal por-
tion of Tmem27 is cleaved and shed from b cells an expression
vector (pTmem27-HA) was generated in which a nine amino acid
HA-epitope tag was inserted downstream of amino acid resi-
dues 39 of the Tmem27 protein (Figure 4A). MIN6 cells trans-
fected with this vector released a protein in the supernatants
that could be detected with an anti-HA antibody and had a sim-
ilar size as untagged Tmem27. This protein was not detected in
control cells or cells expressing the untagged protein (Figure 4G).
Together, these data demonstrate that Tmem27 is a pancreatic
b cell-specific, cleaved and shed transmembrane protein.
Tmem27 is a constitutively shed plasma
membrane protein
To localize Tmem27 in pancreatic b cells, we performed immu-
nofluorescence studies using anti-Tmem27N and –C antibodies.
MIN6 or dispersed pancreatic islets were grown on slides, fixedCELL METABOLISM : DECEMBER 2005
Regulation of pancreatic islet massand permeabilized and treated with primary antibodies raised
against insulin and synaptophysin (Syn), specific markers for
insulin-containing dense-core granules and synaptic-like micro-
vesicles, respectively (Wiedenmann et al., 1988). Neither insulin
nor synaptophysin colocalized with Tmem27, demonstrating
that Tmem27 is not a constituent of these organelles (Figure 5A).
Specific staining of Tmem27 was detected in the perinuclear
compartment and on the plasma membrane. Plasma membrane
staining of Tmem27 colocalized with membrane immunore-
activity of Glut2, further supporting that Tmem27 is a surface-
membrane protein. We also studied Tmem27 by electron mi-
croscopy and observed nanogold particles associated with the
plasma membrane in proximity to vesicle /membrane fusion
events (Figures 5B and 5C). To further investigate the release of
the cleaved form of Tmem27 we stimulated isolated pancreatic
islets cells with low (2.8 mM) and high (11.1 mM) glucose concen-
trations. Whereas insulin secretion increased when stimulated
with glucose we did not measure a change in Tmem27 concen-
trations in the supernatant of these cells (Figure 5D). Lastly, we
performed pulse-chase experiments using 35S-methionine to
determine the kinetics of uncleaved and soluble Tmem27 pro-
teins. [35S]methionine incorporation in Tmem27 was calculated
from band densities on scanned autoradiography films. Relative
immunoprecipitated radioactivity on the gels showed that
[35S]methionine was incorporated in Tmem27 protein for up to
3 hr after the start of the chase period. This time point is denoted
as 100% incorporation (Figure 5E). The half-life of Tmem27 from
linear regression analysis of the data points was determined to
bew27 hr. [35S]-labeled, soluble Tmem27 was immunoprecipi-
Figure 3. Tmem27 is an N-glycosylated protein and forms dimers
A) MIN6 cells were incubated with increasing amounts of tunicamycin, which in-
hibits glycosylation at asparagine residues. Addition of DMSO alone to the cells
had no effect.
B) MIN6 cell lysates were incubated with either PBS, or cross-linking reagents
dimethyl 3, 30-dithiobispropionimidate (DTBP) and bismaleimidohexane (BMH).
SDS-PAGE under nonreducing conditions and immunoblotting using anti-
Tmem27C antibodies showed a band twice the molecular weight of full-length
Tmem27. Under reducing conditions, only the monomer was detected in PBS
and DTBP-treated cell lysates. In contrast, the dimer persisted in BMH-treated
samples as BMH cross-linking could not be reversed.CELL METABOLISM : DECEMBER 2005tated from MIN6 supernatants and quantitated by scintillation
counting after PAGE. Relative radioactivity present in the bands
over a period of 24 hr revealed that the amount of cleaved
Tmem27 in the supernatant of MIN6 cells increased linearly
and by approximately 10% every hour. These data show that
soluble Tmem27 is shed into the supernatant in a constitutive
manner.
Increased expression of TMEM27 in mouse models with
islet hypertrophy and enhanced b cell replication in vitro
We measured expression of Tmem27 in hypertrophied islets of
ob/ob, db/db and aP2-Srebp-1c transgenic mice (Shimomura
et al., 1998). Pancreatic islets from 6- to 8-week-old mice
were isolated and gene expression levels were compared to
their wild-type littermates. Using real-time PCR we found a
1.7, 1.7, and 2.7-fold increase in Tmem27 levels of ob/ob,
db/db, and aP2-Srebp-1c islets, respectively, compared to con-
trols (Figure 6A). In addition, islets isolated from these mice ex-
hibited an increase in secretion of cleaved Tmem27 into the me-
dium compared to size-matched islets of wild-type littermates
(Figure 6B, data not shown). To study if Tmem27 stimulates pan-
creatic b cell replication, we examined the effect of Tmem27
expression on the proliferation of MIN6 cells. Cells were electro-
porated with either siRNAs targeting Tmem27 or plasmid
pTmem27. Cell replication was assessed by cell counting and
measuring incorporation of [3H]thymidine 48 hr after electro-
poration (Figures 6C and 6D). MIN6 cells that were transfected
with pTmem27 exhibited w5-fold overexpression compared
to pcDNA3-transfected cells and showed w2-fold increase in
[3H]thymidine incorporation and increased cell density 48 hr af-
ter plating. In contrast, MIN6 cells that had reduced expression
of protein following siRNA treatment showed lower [3H]thymi-
dine incorporation and cell density (Figures 6C and 6D). Further-
more, we did not observe any changes in apoptosis in cells with
increased or reduced expression of Tmem27 (data not shown),
suggesting Tmem27 does not affect cell death. To further eluci-
date if the full-length, truncated, or soluble form of Tmem27
stimulated b cell replication in vitro we generated a Tmem27 mu-
tant (pTmem27-V5.del.) in which amino-acid residues 17-129
were deleted. Transfection of pTmem27-V5.del. in MIN6 cells
led to the expression of a truncated protein of w30 kDa (Fig-
ure 6E). [3H]thymidine incorporation assays demonstrated that
expression of the full-length Tmem27 increased replication not
only in MIN6 cells but also in HepG2 and HEK293 cells. In con-
trast, overexpression of the truncated Tmem27 form showed no
effect (Figure 6F). Since non-b cell lines do not release the solu-
ble Tmem27 form these data demonstrate that the full-length
form of Tmem27 is responsible for the proliferation response. In-
dependent evidence that the soluble form has no effect on cell
replication was obtained from coculture and conditioned me-
dium experiments in which cells were cultured with increasing
concentrations of soluble Tmem27 (data not shown). Together,
these results demonstrate that the full-length form of Tmem27
stimulates cell proliferation in MIN6 and other cell types.
Trangenic mice overexpressing Tmem27 in pancreatic
islets exhibit islet hypertrophy
We generated two independent pancreatic b cell-specific trans-
genic lines following pronuclear microinjection of a vector con-
struct in which the murine Tmem27 cDNA is under the control
of the rat insulin promoter. RT-PCR and immunoblot analysis389
A R T I C L EFigure 4. TMEM27 is cleaved and released from b cells of the islet
A) Schematic drawing of TMEM protein domains, including regions against which antipeptide antibodies were raised and epitopes were inserted. Numbers denote posi-
tions of amino acid residues. S, signal peptide sequence; TM, transmembrane domain; N-Gly, N-glycosylation sites; HA, position of HA-epitope insertion; V5, position of
V5-epitope insertion; Tmem27N and Tmem27C indicate positions of sequences used for antipeptide antibody production.
B) Anti-Tmem27C antibody in Western blots of MIN6 cells detected two bands for Tmem27 (left panel). The 25 kDa band became more abundant in cells that were trans-
fected with pTmem27.V5.
Immunoblots of cell lysates from above were probed with a-V5 antibody (right panel). The antibody against the V5-epitope also detected both bands in pTmem27.V5-trans-
fected cells but not in pcDNA3-transfected cells.
C) Denoted cell lines were transfected with pcDNA3 or pTmem27 and full-length protein was detected with anti-Tmem27C in Western blots of cell lysates. Soluble protein
was detected with anti-Tmem27N only in the supernatant of MIN6 cells. Increased expression of full-length protein led to increased amounts of soluble protein solely in the
MIN6 cells. Supernatants were collected after 48 hr and normalized to protein content of cell lysates.
D) Mouse pancreatic islets were isolated and incubated for 72 hr. Supernatants were collected and islets were transferred in lysis buffer. Full-length protein was detected
with anti-Tmem27C in Western blots of lysates and soluble protein was detected with anti- anti-Tmem27N in Western blots loaded with equal volumes of the supernatant.
E) Supernatant from MIN6 cells was incubated with N-glycanase. The molecular weight shift in the Western blot indicates that the enzyme removed sugar moieties from
soluble Tmem27. Soluble protein was detected with anti-Tmem27N antibody.
F)MIN6 cells were electroporated with siRNAs targeting GFP or Tmem27. In the cells that were electroporated with si-Tmem27#1 and #2, reduction in the levels of Tmem27
protein was detected with anti-Tmem27C 48 hr after electroporation. SDS-PAGE was run with supernatants from the same cells and reductions in the levels of soluble
proteins were detected with anti-Tmem27N. Supernatants were collected after 48 hr and normalized to protein content of cell lysates.
G) MIN6 cells were electroporated with pcDNA3, pTmem27 or pTmem27-HA. Overexpression of Tmem27 was detected by Western blotting of cell lysates with anti-
Tmem27C antibodies. Supernatants from the same cells were collected after 48 hr and subjected to Western blotting with anti-HA epitope antibody.390 CELL METABOLISM : DECEMBER 2005
Regulation of pancreatic islet massFigure 5. Tmem27 is located in secretory vesicles and on plasma membranes of pancreatic b cells
A) Isolated mouse islets were dispersed and stained with anti-Tmem27C and anti-Insulin, anti-Synaptophysin, or anti-Glut-2 antibodies.
B) Electron microscopy performed on MIN6 cells with anti-Tmem27C antibodies localized Tmem27 in small secretory vesicles (arrows). IgG conjugated to 10 nm gold
particles was used for detection of the antibody.
C) Using the same method as in (B), vesicles that contain Tmem27 were detected during fusion events with the plasma membrane (arrow).
D) An equal number of size-matched mouse islets were incubated in either 2.8 mM or 11.1 mM glucose. Supernatants were collected after 72 hr and soluble Tmem27 levels
were quantified and normalized to protein content of islet lysates. Secreted insulin levels were measured after 6 hr incubation in the same supernatant. **p < 0.0002.
E) [35S]Methionine incorporation into Tmem27 was measured in MIN6 cells during a pulse-chase experiment over 24 hr.showed that Tmem27 expression in both lines wasw4-fold in-
creased in pancreatic islets compared to wild-type littermates
(Figure 7A). We studied the islet mass at ages 10 and 20 weeks
in transgenic animals by pancreatic islet morphometry. Trans-
genic mice exhibited normal islet morphology (based on immu-
nohistochemistry using insulin/glucagon costaining) but had an
approximately 1.5- and 2-fold increase in islet mass at 10 and 20
weeks, respectively, compared to wild-type littermates (Figures
7B and 7C, data not shown). No difference was found in the
mass of non-b cells (a-, g-, and d cells) (Figure 7D). The increase
in b cell mass was further validated by measuring the total insulin
content of transgenic and wild-type mice. The total insulin con-
tent was also increased in transgenic mice overexpressing
Tmem27 (Figure 7E). To rule out that increased insulin resis-
tance was responsible for the observed increase in b cells mass
we performed insulin-tolerance tests (ITT). No difference in glu-
cose clearance following a bolus insulin injection was observed
(data not shown). Furthermore, no significant difference in body
weight, fasting insulin levels, plasma leptin concentrations and
adiponectin levels were measured in transgenic mice compared
to control littermates (data not shown). These data show thatCELL METABOLISM : DECEMBER 2005insulin resistance is not responsible for the increased b cell
mass observed in the transgenic animals. Increased b cell rep-
lication may lead to decreased glucose responsiveness due to
dedifferentiation. Therefore, we performed glucose tolerance
tests and studied insulin secretion from islets that were isolated
from either wild-type or transgenic animals. Transgenic mice
exhibited normal glucose tolerance (data not shown) and we ob-
served a robust w13-fold increase in insulin secretion of islets
isolated from transgenic mice in response to glucose stimula-
tion, comparable to wild-type controls (Figure 7F). Together,
these data demonstrate that Tmem27 stimulates islet growth
in vivo and that increased expression of Tmem27 does not im-
pair regulated insulin secretion and glucose sensing.
Discussion
In this study we used a genomic approach to identify genes that
may contribute to maintenance of islet mass during adult life and
enhancing islet growth when the demand for insulin secretion in-
creases. We found that Tmem27 exhibits markedly reduced ex-
pression in diabetic Tcf1–/– animals with decreased islet mass391
A R T I C L EFigure 6. Tmem27 increases b cell replication
in vitro
A) Tmem27 expression levels were measured in
islets isolated from ob/ob, db/db, aP-Srebp-1c and
wild-type littermate control mice with quantitative
RT-PCR. Tmem27 expression was evaluated relative
to b-actin levels in the same sample. **p < 0.01.
B) Isolated islets from wild-type and ob/ob mice
were matched for number and size and incubated
in equal volumes of media for 72 hr. Soluble protein
was detected with anti-Tmem27N.
C) MIN6 cells were electroporated with siRNAs
targeting luciferase or Tmem27 and pcDNA3 or
pTmem27. Cells were trypsinized 48 hr after electro-
poration, stained with trypan blue and counted with
a hemocytometer. Each value represents a mean of
six independent experiments. **p < 0.01.
D) MIN6 cells were electroporated as denoted and
cell replication was measured by [3H]thymidine in-
corporation. **p < 0.01.
E) MIN6 cells were electroporated with pcDNA3,
pTmem27-V5, or pTmem27-V5del., which lacks
amino acid residues 17-129. The deletion mutant is
expressed as aw30 kDa protein.
F) MIN6, HepG2 and HEK293 cells were transfected
with pcDNA3, pTmem27-V5 or pTmem27-V5.del.
Cell replication was measured by [3H]thymidine in-
corporation. **p < 0.01.compared to wild-type littermates. Tmem27 is essential for op-
timal b cell growth in vitro and transgenic mice overexpressing
Tmem27 exhibit increased islet mass. Promoter analysis and
chromatin immunoprecipitation demonstrate that Tcf-1 binds
to conserved TCF1 binding sites in the Tmem27 promoter and
that it activates transcription of this gene.
Tmem27 is a homolog of angiotensin-converting enzyme-
related carboxypeptidase (ACE2) and has previously been local-
ized to the luminal surface and cytoplasm of collecting ducts
(Zhang et al., 2001; Turner and Hooper, 2002). During the devel-
opment of mouse kidney, Tmem27 is detectable at day 13 of
gestation in the ureteric bud branches. Its expression is progres-
sively increased during later stages of the gestation extending
into the neonatal periods and then is decreased in adult life
(Zhang et al., 2001). Interestingly, we found normal levels of
Tmem27 mRNA in the kidneys of Tcf1–/– animals (data not
shown). Tcf1 expression in adult kidneys is restricted to the
proximal and distal tubules, whereas Tcf2, a related protein
that can form heterodimers with Tcf1 and shares 93%, 75%
and 47% sequence identity in their DNA binding domains, di-
merization domains, carboxyl-terminal activation domains,392respectively, is mainly localized in the collecting ducts (Rey-
Campos et al., 1991; Coffinier et al., 1999). Tmem27 is specifi-
cally expressed in the collecting tubules and therefore overlaps
in its expression with Tcf2, indicating that Tcf2 homodimers may
regulate the expression of Tmem27 in these cells in the adult
kidney. In pancreatic islets of Tcf1–/– mice, Tmem27 expression
is profoundly reduced, indicating that Tcf2 cannot substitute for
Tcf1. This may be explained by different DNA binding specific-
ities and/or by the higher Tcf1 expression levels compared to
Tcf2 in pancreatic islets.
We found that Tmem27 is expressed at the earliest stages of
pancreatic development (E10.5). Tmem27 is expressed in
hormone-positive cells throughout development but becomes
restricted to pancreatic b cells in the postnatal period. We did
not detect Tmem27 expression in Ngn3-positive neuroendo-
crine precursor cells (data not shown). This expression pattern
is reminiscent of the temporal and spacial expression of Pdx-1,
an essential transcription factor for pancreas development, dif-
ferentiation and insulin gene transcription (Jonsson et al., 1994;
Offield et al., 1996; Ahlgren et al., 1998). Indeed, we have iden-
tified a conserved binding site of Pdx-1 in the Tmem27 promoterCELL METABOLISM : DECEMBER 2005
Regulation of pancreatic islet massFigure 7. Increased expression of Tmem27 in pan-
creatic b cells leads to increased islet mass
A) Increased expression of Tmem27 was detected
with anti-Tmem27C in Western blots of islets isolated
from RIP-Tmem27 transgenic mice and wild-type lit-
termate controls.
B) Immunohistochemistry of whole pancreata from
transgenic and control littermate mice (n = 3). Cross-
sections were embedded in paraffin and stained for in-
sulin using anti-insulin antibodies. Images are repre-
sentative of each genotype at 5x magnification.
C) Insulin staining in 7 mm sections was quantified us-
ing Metamorph software. At least 50 islets were quan-
tified for each pancreas in sections greater than
200 mm apart. *p < 0.05.
D) Quantification of non-b cells of islets was per-
formed by immunostaining with a cocktail consisting
of anti-glucagon, somatostatin and pancreatic poly-
peptide antibodies. Analysis was carried out as in (C).
E) Whole pancreata from transgenic and wild-type
mice (n = 5) were isolated and homogenized in acid/
ethanol. Insulin content was normalized per pancreas
weight. *p < 0.05.
F) Insulin secretion of size-matched islets of trans-
genic mice and wild-type littermates in response to
glucose.that partially overlaps with the Hnf1 site and which exhibits bind-
ing activity in EMSA analysis (Figures 1B and 1D), suggesting
that Pdx-1 may also be a critical regulator of Tmem27. These
data make it tempting to speculate that the membrane–bound
or soluble form of Tmem27 contributes to the defect observed
in Pdx-1 deficient mice, possibly by acting as a receptor or a sig-
naling molecule (Johnson et al., 2003).CELL METABOLISM : DECEMBER 2005We found that the N-terminal, extracellular domain of
Tmem27 is cleaved and released from the plasma membrane
of pancreatic b cells. Tmem27 does not colocalize with insulin
granules or synaptic-like microvesicles, thereby ruling out the
possibility that Tmem27 is released by the regulated secretory
pathway. This is further supported by the observation that the
cleaved protein cannot be detected in whole-cell extracts of393
A R T I C L EMIN6 cells and that release of the cleaved form of Tmem27 is not
regulated by glucose. Interestingly, cleavage of Tmem27 only
occurs in pancreatic b cells and could not be detected in cells
thatwere transfectedwitha Tmem27expressionvector. Thismay
suggest that Tmem27 is cleaved by a b cell-specific or -enriched
protease. Receptor shedding has been reported for members of
diverse families of transmembrane receptors. For instance, the
precursor form of hepatocyte growth factor is associated with
the cell surface and biological function is dependent on proteo-
lytic cleavage of an extracellular domain by the serine protease
hepatocyte growth factor activator (HGFA)(Naldini et al., 1992;
Miyazawa et al., 1993). Other receptors can bind to ligands
upon cleavage and inhibit their activity. One example is the
growth hormone binding protein (GHBP), which derives from
proteolytic shedding of the GH receptor (GHR) extracellular do-
main and is complexed to a substantial fraction of circulating GH
(Wang et al., 2002). Proteolytic shedding of receptors may not
just release ligands or ligand binding proteins but can also be a
means to regulate receptor function. For instance, one of the
mechanisms that has evolved to modulate TNF function is the
proteolytic cleavage of its cell surface receptors (Xanthoulea
et al., 2004). The biological relevance is highlighted by identi-
fications of mutations affecting shedding of the p55TNF recep-
tor that have been linked with the development of the TNFR-
associated periodic syndromes (McDermott, 2001). Our studies
support a model by which the full-length, membrane-bound form
of Tmem27 is responsible for stimulating cell replication: i. Over-
expression of full-length Tmem27 in b cell lines and non-b cells
that do not cleave Tmem27 leads to increased cell replication,
ii. Overexpression of a truncated form in b cells and non-b cells
has no effect on cell replication, and iii. Conditioned media or co-
culture experiments failed to provide evidence that the soluble
form of Tmem27 stimulates cell replication. These studies indi-
cate that identification of the cleavage enzyme that processes
Tmem27 could be therapeutically used to develop drugs that in-
hibit the activity of this protease. Such an inhibitor may therefore
reduce cleavage of Tmem27 and lead to constitutive receptor
activation, thereby increasing b cell mass. The role of the extra-
cellular, soluble form of Tmem27 is currently unknown and future
studies need to establish if it serves as a ligand, a ligand binding
protein or a receptor. However, its unique properties, including
pancreatic b cell-specific and constitutive release, make it
tempting to hypothesize that it may be exploited in the future
as a biomarker for islet mass if sensitive RIAs or ELISAs can be
developed to detect this protein in serum samples.
In this study we have also established that Tmem27 controls
islet growth in vivo. The expression of Tmem27 is reduced in
Tcf-1–/– mice and increased in three animal models of islet hy-
pertrophy: ob/ob, db/db and aP2-Srebp-1c transgenic mice. It
is interesting that expression of Tmem27 is also increased in
the hypertrophic kidneys after renal ablation, indicating that it
may play a role in compensatory growth responses to organ in-
jury (Zhang et al., 2001). Significantly, two independent lines of
transgenic mice with increased expression of Tmem27 in pan-
creatic b cells exhibited a w2-fold increase in pancreatic islet
mass and insulin content. Overexpression of Tmem27 in b cells
had no effect on non-b cell mass, further supporting the notion
that the full-length, membrane bound form is responsible for
stimulating cell growth. Although under normal chow diet we
did not observe alterations of glucose homeostasis, increased
b cell mass together with unaltered glucose sensing will likely be394beneficial in insulin-resistant states. Future studies with loss-of-
function and gain-of-function mutations will further elucidate the
role of Tmem27 in the maintenance of islet mass and insulin se-
cretion. Such studies will validate Tmem27 or its inactivating
protease as a novel pharmacological target for the treatment
of diabetes.
Experimental procedures
Experimental animals
All animal models were housed in Laboratory of Animal Research Center
(LARC), a pathogen-free animal facility at the Rockefeller University. The an-
imals were maintained on a 12 hr light/dark cycle and fed a standard rodent
chow. Genotyping of transgenic mice was performed on DNA isolated from
3 weeks old mice by PCR (Lee et al., 1998).
Vectors
The reporter plasmid pT27luc-wt was generated by cloning an 815 bp frag-
ment of the mouse Tmem27 promoter into pGL2-luciferase. The reporter
plasmids pT27luc-m1 and -m2 are identical to pT27luc-wt except for mu-
tated TCF1 binding sites at positions 256 to –59 and –116 to –119. Vector
pTmem27.V5 is generated by cloning a PCR fragment of 696 bp that encom-
passes 30 bp of 50UTR of Tmem27 cDNA and the rest of the open reading
frame except for the stop codon into pcDNA3.1/V5-His-TOPO vector from
Invitrogen. Vector pTmem27-V5.del. was generated by deleting amino acid
residues 17–129 of pTmem27.V5 vector using a PCR approach. The se-
quences of all constructs were confirmed by DNA sequencing.
Antibodies
Two peptides (anti-Tmem27N: VQSAIRKNRNRINSAFFLD and anti-
Tmem27C: GIPCDPLDMKGGHINDGFLT) were synthesized and processed
to >90% purity, conjugated to KLH and used for immunization of rabbits
(Bethyl Laboratories, Texas). Antisera were affinity purified and tested by
western blotting and immunohistochemistry. Affinity purified antisera were
used for all studies. Other antibodies used for immunoblotting and immuno-
histochemistry were obtained from the following sources: anti-insulin (Linco),
anti-glucagon (Linco), anti-V5 (Invitrogen), anti-Tcf1 (Active Motif), anti-HA
(Covance), anti-Glut2 (R&D Systems), anti-synaptophysin (Chemicon), anti-
somatostatin (Cell Marque), anti-PP (Linco), and anti-Pdx1 (gift from Chris
Wright). Rhodamine red conjugated donkey anti-guinea pig (Jackson
Labs), Alexa 488 donkey anti-rabbit (Molecular Probes).
Cell culture
MIN6 cells were cultured with DMEM medium containing 25 mM glucose,
15% fetal bovine serum, and 5.5 mM 2-mercaptoethanol. INS-1 cells were
cultured with RPMI 1640 medium containing 11.1 mM glucose and 5% fetal
bovine serum and 10 mM Hepes (pH 7.4). HepG2 cells were cultured with
DMEM medium containing 25 mM glucose and 10% fetal bovine serum. Pan-
creatic islets were cultured in RPMI-1640 medium.
Transient transfections and luciferase assay
Fugene reagent (Roche) for HepG2 cells and Lipofectamine 2000 (Invitrogen)
for MIN6 cells were used according to the manufacturer’s directions in tran-
sient transfections. 0.5 mg of luciferase reporter construct, expression vector
and CMV-LacZ were added per 35 mm dish. Luciferase was normalized for
transfection efficiency by the corresponding b-galactosidase activity (Shih
et al., 2001).
Crosslinking of proteins in cell lysates
MIN6 cells, grown to 90% confluency in 6 well plates, were harvested and re-
suspended in reaction buffer and reagent in 50 ml volume and incubated for
2 hr at 4ºC. Reactions were stopped by adding 50 mM Tris-HCl (pH 7.4) for
10 min on ice. Cells were then washed with PBS and lysed in RIPA buffer in
the presence of protease inhibitors for 15 min at 4ºC. Cell lysates were centri-
fuged for 5 min at 10,0003 g and the supernatants were subjected to reduc-
ing and nonreducing SDS-PAGE followed by immunoblotting. Crosslinking
reagents and buffers: BMH (Pierce) was dissolved in DMSO and incubated
in PBS, and DTBP (Pierce) was dissolved in water and incubated in 0.2 M tri-
ethanolamine (pH 8.0).CELL METABOLISM : DECEMBER 2005
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MIN6 cells that express pV5-TMEM27 were incubated with indicated con-
centrations of tunicamycin (Sigma) dissolved in DMSO and with DMSO alone
for 12 hr at 37ºC. Cell lysates were then subjected to SDS-PAGE and immu-
noblotting with anti-V5 antibody.
Intact N-linked glycans were removed from the soluble portion of TMEM27
with the recombinant enzyme N-glycanase (Prozyme, San Leandro, CA).
Supernatants from MIN6 cells and pancreatic islets were denatured in
20 mM sodium phosphate (pH 7.5), 0.1% SDS, and 50 mM b-mercaptoetha-
nol by heating at 100ºC for 5 min. NP-40 was added to a final concentration of
0.75% and reaction was incubated with N-glycanase for 3 hr at 37ºC.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) analysis was performed as de-
scribed previously (Shih et al., 2001) with minor modifications. Assay was
performed with 10 mg of whole-cell extracts in binding buffer (20 mM Hepes
[pH 7.9], 10% glycerol, 150 mM NaCl, 1 mM DTT). Whole-cell extracts were
incubated with 32P-labeled double-stranded oligonucleotide probes contain-
ing the wild-type or mutant Tcf1 binding sites in the TMEM27 promoter
(sequences: 50-GGAGATTTTCGTAAATAACTGACA -30, 50-GGGCGTTAATT
ATTAAACCTTTTA-30 and 50-GGGCAGAGATTATTAAACCTTTTA-30, respec-
tively). Cold competitor was an unlabeled double-stranded oligonucleotide
containing the Tcf1 binding site in the Fxr-1 promoter (sequence: 502GAT
GGGGGTTAATCAAGTAAACCACAC230). Supershifts were carried out with
an anti-Tcf1 antibody (Geneka Biotechnology Inc., Montreal, Canada).
ChIP analysis was carried out using isolated primary hepatocytes and iso-
lated islets from C57/B6 mice or MIN6 cells, and the ChIP Assay kit (Upstate
Cell Signaling Solutions, Lake Placid, NY) according to the manufacturers
protocol. Tcf1 was precipitated with anti-HNF-1a antibody and DNA was
amplified using primers sequences: 50-ACAGGAGGCAGGTGGGAGGCTT
CT -30 and 50-CCCGGATTAGGGTATCGGAGAA -30). Primers for apoM
were 50-GGGCTCAGCTTTCCTCCTA-30 and 50-CTCCGCCTTAACTGTTCTC
TGATG -30).
Whole-cell extract preparation
MIN6 cells were grown to 90% confluency in 150 mm tissue culture dishes.
Cells were washed once in ice-cold PBS and scraped into 3 ml PBS. Cells
were centrifuged at 4,0003 g for 4 min and resuspended in 2 volumes of high-
salt extraction buffer (400 mM KCl, 20 mM Tris [pH 7.5], 20% glycerol, 2 mM
DTT, 1x complete TM protease inhibitors (Boehringer Mannheim), and 20 mg/
mL Aprotinin). Cell-lysis was performed by freezing and thawing, and the cel-
lular debris was removed by centrifugation at 16,000 3 g for 10 min at 4ºC.
Pulse-chase experiment with 35S-labeled Tmem27
23 105 MIN6 cells were plated in 35 mm dishes and incubated in methionine-
free DMEM (DMEM-Met) for 70 min at 37ºC. 200 mCi/mL of [35S]methionine
was added to DMEM-Met and cells were labeled in this media for 2 hr at
37ºC. At the end of the pulse period, MIN6 cells were chased with complete
growth medium for different periods. At the indicated time points, superna-
tants were collected and cells were lysed for immunoprecipitation. Cells
were washed in ice cold PBS five times and scraped into PBS and centri-
fuged for 5 min at 2000 rpm. Cells were suspended in lysis buffer (20 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP40, 1mM EDTA and protease inhib-
itors) and sonicated 5 s for 4 times. 0.25% sodium deoxycholate was added
to the samples, which were then mixed and incubated on ice for 15 min. Sam-
ples were centrifuged for 15 min at max speed at 4ºC and the supernatant
from the lysates were immuno-precipitated with a-Tmem27C for 16 hr at
4ºC followed by incubation with Protein G-Sepharose for 1 hr. Collected
MIN6 supernatants were adjusted to 20 mM Tris-HCl (pH 7.4) and 1%
NP40 along with protease inhibitors. a-Tmem27N antibodies were used to
immunoprecipitate cleaved protein for 16 hr at 4ºC followed by incubation
with Protein G-Sepharose for 1 hr. The sepharose beads were washed in
ice-cold PBS 5-times for 5 min each and resuspended in SDS sample buffer
(2% SDS, 62.5 mM Tris [pH 6.8]). Samples were boiled for 5 min and super-
natants were run on 4%–15% gradient SDS gels. Gels were processed for
autoradiography and exposed on film.
In vitro insulin secretion and hormone measurements
Mouse islets were isolated and incubated in different glucose concentrations
after an overnight culture. Insulin and glucagon were extracted from pan-CELL METABOLISM : DECEMBER 2005creata with acid ethanol (10% glacial acetic acid in absolute ethanol), soni-
cated for 10 min, and centrifuged 2 times at 4ºC at 12,000 3 g for 10 min.
Supernatants were collected and stored at 220ºC for insulin and glucagon
determinations by using sensitive RIA kits (Linco Research).
Pancreatic islet and RNA isolation
Pancreatic islets were isolated from 6 to 8 week-old mice. We used collage-
nase digestion and differential centrifugation through Ficoll gradients, with
a modification of procedures previously described (Shih et al., 2002). Total
RNA was then extracted using TRIzol reagent (Gibco-BRL) and following
the manufacturer’s instructions. Contaminating genomic DNA was removed
using 1ml of RNase free DNase-I (Boehringer) per 5mg of RNA.
Islet morphometry
The pancreata were fixed in paraformaldehyde and stained for insulin and
pool of glucagon, pancreatic polypeptide and somatostatin as described
above. Sections (7mm) through the entire pancreas were taken, and every
sixth section was used for morphometric analysis. At least 288 nonoverlap-
ping images (pixel size 0.88mm) were scanned using a confocal laser-
scanning microscope (Zeiss LSM 510, Germany). The parameters measured
in this study were analyzed using integrated morphometry analysis tool in the
Metamorph Software Package (Universal Imaging Corporation, PA). The area
covered by cells stained by insulin or non-b cell pool was integrated using
stained objects that are greater than 10 pixel in size.
RT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen) and 10 mg of RNA
was treated with 5U of RNase-free DNase-I (Ambion). cDNA was synthesized
using Moloney leukemia virus reverse transcriptase with dNTPs and random
hexamer primers (Invitrogen). The cDNAs provided templates for PCRs using
specific primers in the presence of [a-32P]dCTP and Taq polymerase as pre-
viously described (Shih et al., 2001). Quantitative PCR was performed using
the Sequence Detection System 7700 (Applied Biosystems) for amplification
and specific sequence detection. Forward and reverse PCR primers were
used at a final concentration of 300 nM, and probes, containing a 50 fluoro-
phor (6-FAM) and a 30 quencher (TAMRA), were used at a final concentration
of 100 nM. Expression of Tmem27 was evaluated relative to the mRNA ex-
pression of the housekeeping gene b-actin in the same sample. Cycling pa-
rameters were: 2 min, 50ºC; 10 min, 95ºC; and 40 times: 30 s, 95ºC; 1 min,
60ºC. Primers and probes were purchased from Applied Biosystems.
Immunoblotting and immunohistochemistry
Cytosolic protein extracts were separated by SDS-PAGE (4%–15%) and
transferred onto a nitrocellulose membrane (Schleicher & Schuell) by electro-
blotting. TMEM27 was detected with anti-Tmem27N and anti-Tmem27C
antisera (1:500). Membranes were incubated with primary antibodies over-
night at 4ºC. Incubations containing the secondary antibody were performed
at RT for 1 hr. SDS-PAGE under nonreducing conditions was performed un-
der conditions omitting DTT from the sample buffer.
MIN6 cells were plated on coated slides (Nalge Nunc Int.) and fixed with
4% paraformaldehyde at 4ºC for 20 min. Mouse islets were dissociated for
5 min at 37ºC in the presence of 0.01% Trypsin-EDTA and were plated in col-
lagen coated slides and fixed the same way. Slides were incubated in 0.01%
saponin with 3% normal donkey serum in PBS for 30 min at room tempera-
ture and anti-Tmem27N and anti-Tmem27C (1:20) were added overnight at
4ºC along with anti-insulin (1:600), anti-Glut2 (1:50), and anti-synaptophysin
(1:500). Secondary antibodies were added for 30 min at RT.
Pancreata were fixed in 4% paraformaldehyde at 4ºC for 4 hr and embed-
ded in paraffin. 7 mm sections were cut and after deparaffinization, antigen-
unmasking was performed by microwaving slides in 0.01 M sodium citrate
(pH 6.0). Sections were permeabilized in 0.1% Triton-X-100 and incubated
in 3% normal donkey serum in PBS for 30 min. Staining was completed as
above.
Electron microscopy studies
MIN6 cells were fixed in 4% paraformaldehyde and 0.02% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.4) for 2 hr. The cells were washed with PBS
and embedded in 10% gelatin and refixed as above. Cell pellets were cryo-
protected using a 2.3M sucrose solution in PBS, and samples were stored in
liquid nitrogen until use (Griffiths et al., 1983). Cryo, ultrathin sections were395
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sections were collected on Formvar-carbon coated nickel grids, blocked
with 1% BSA-PBS and incubated with anti-Tmem27C at a 1:10 dilution. In-
cubation was stopped by washing 2 times with PBS, 15 min each. The sec-
tions were then incubated with goat anti-rabbit IgG conjugated to 10 nm gold
particles (Amersham Life Science, Arlington Heights, IL). The grids were pro-
cessed and stained as desribed previously (Tokuyasu, 1973).
Thymidine incorporation studies
[3H]Thymidine incorporation in 53 104 cells/well in 24-well culture plates was
assayed as follows. 48 hr after electroporation, cells were incubated in
growth arrest medium (0.5% FCS) for the next 24 hr and then incubated
for an additional 24 hr in normal growth medium. For the last 4 hr of the incu-
bation, 0.25 mCi/well [3H]methylthymidine (Perkin Elmer) was added. After
completion, cells were rinsed twice in ice-cold PBS, and incubated with
10% trichloroacetic acid (TCA) on ice for 20 min. After washing with 10%
TCA, cells were solubilized in 0.2M NaOH/1% SDS for 10 min at room tem-
perature. TCA-insoluble materials were neutralized with 0.2M HCl, and radio-
activity was determined by a liquid scintillation counter.
RNA interference
Synthetic siRNAs were synthesized by Dharmacon Research (Lafayette, CO).
siRNAs were designed for mouse TMEM27 (NM_020626) and Luciferase. The
target sequences of siRNAs are: siTMEM27#1: gaagtacagtcggccataa, siT-
MEM27#2: ctacctatgctgatttaat. 3mg of each siRNA per 1 3 106 cells were
electroporated into MIN6 cells.
Statistical analysis
Results are given as mean6 SD. Statistical analyses were performed by us-
ing a Student’s t test, and the null hypothesis was rejected at the 0.05 level.
Supplemental data
Supplemental Data include Supplemental Experimental Procedures and can
be found with this article online at http://www.cellmetabolism.org/cgi/
content/full/2/6/385/DC1/.
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